205 related articles for article (PubMed ID: 23945392)
1. Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Berge EM; Aisner DL; Doebele RC
J Thorac Oncol; 2013 Sep; 8(9):e83-4. PubMed ID: 23945392
[No Abstract] [Full Text] [Related]
2. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
Ackerman A; Goldstein MA; Kobayashi S; Costa DB
J Thorac Oncol; 2012 Oct; 7(10):e19-20. PubMed ID: 22982663
[No Abstract] [Full Text] [Related]
3. Personalized medicine and inhibition of EGFR signaling in lung cancer.
Gazdar AF
N Engl J Med; 2009 Sep; 361(10):1018-20. PubMed ID: 19692681
[No Abstract] [Full Text] [Related]
4. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
Pennell NA; Yin L; Keshtgarpour M; Ma PC
J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
[No Abstract] [Full Text] [Related]
5. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
Costa DB; Schumer ST; Tenen DG; Kobayashi S
J Clin Oncol; 2008 Mar; 26(7):1182-4; author reply 1184-6. PubMed ID: 18309959
[No Abstract] [Full Text] [Related]
6. Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
Aydiner A; Yildiz I; Seyidova A
Asian Pac J Cancer Prev; 2013; 14(5):3255-61. PubMed ID: 23803112
[TBL] [Abstract][Full Text] [Related]
7. Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.
Hellmann MD; Reva B; Yu H; Rusch VW; Rizvi NA; Kris MG; Arcila ME
J Thorac Oncol; 2014 Oct; 9(10):e73-4. PubMed ID: 25521405
[No Abstract] [Full Text] [Related]
8. Serum concentrations of Erlotinib at a dose of 25 mg daily.
Costa DB; Kobayashi S; Yeo WL; Hamada A
J Thorac Oncol; 2010 Aug; 5(8):1311-2. PubMed ID: 20661096
[No Abstract] [Full Text] [Related]
9. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536
[TBL] [Abstract][Full Text] [Related]
10. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Stinchcombe TE; Ramalingam SS
Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
[No Abstract] [Full Text] [Related]
11. EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
Baty F; Rothschild S; Früh M; Betticher D; Dröge C; Cathomas R; Rauch D; Gautschi O; Bubendorf L; Crowe S; Zappa F; Pless M; Brutsche M;
PLoS One; 2013; 8(9):e72966. PubMed ID: 24039832
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Yeo WL; Riely GJ; Yeap BY; Lau MW; Warner JL; Bodio K; Huberman MS; Kris MG; Tenen DG; Pao W; Kobayashi S; Costa DB
J Thorac Oncol; 2010 Jul; 5(7):1048-53. PubMed ID: 20512075
[TBL] [Abstract][Full Text] [Related]
13. Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report.
Fiala O; Pesek M; Finek J; Krakorova G; Benesova L; Minarik M
Tumori; 2014; 100(3):e70-3. PubMed ID: 25076254
[TBL] [Abstract][Full Text] [Related]
14. A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib.
González Manzano R; Martínez Navarro E; Eugenieva E; Fernández Morejón FJ; Farré J; Brugarolas A
Clin Transl Oncol; 2008 Jul; 10(7):442-4. PubMed ID: 18628075
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of tyrosine kinase inhibitor-sensitizing and resistant EGFR mutations in an untreated lung adenocarcinoma patient and response to erlotinib.
Mathur G; Ma D
J Thorac Oncol; 2014 Jul; 9(7):e55-e57. PubMed ID: 24926557
[No Abstract] [Full Text] [Related]
16. [The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Ma Y; Huang Y; Zhao H; Liu J; Chen L; Wu H; Zhou N
Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):203-10. PubMed ID: 23601301
[TBL] [Abstract][Full Text] [Related]
17. Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced
Ortega-Granados AL; Artal-Cortes Á; Aguiar-Bujanda D; Oramas J; Fírvida JL; DE Castro J; Fuentes JC; Gordo R; Galán R; Trigo J;
Anticancer Res; 2019 Mar; 39(3):1317-1328. PubMed ID: 30842164
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
de Lima Araújo LH; da Silveira JS; Baldotto CS; Zukin M; Ferreira CG
J Thorac Oncol; 2012 Jun; 7(6):1059-60. PubMed ID: 22588158
[No Abstract] [Full Text] [Related]
19. Clairvoyance or reliable prediction of the future?
van Zandwijk N; van de Vijver MJ
Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
[No Abstract] [Full Text] [Related]
20. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Dillon B; Naidoo B; Knight H; Clark P
Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
